To test this hypothesis, we developed a co-culture system whereby HER-2 positive tumor cells are co-cultured with MSCs, and the ability of the MSCs to activate Src and modulate downstream drug resistance pathways is observed. This evidence concerns the gene ERBB2 and neoplasm.